A Phase 3, Open-label, Long-Term Study to Evaluate the Safety of LY110140 Once Daily Dosing for 52-week in Japanese Patients With Major Depressive Disorder [SUBSTUDY FOR 700230422]
Phase of Trial: Phase III
Latest Information Update: 24 May 2016
At a glance
- Drugs Fluoxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 23 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 22 Aug 2014 Planned End Date changed from 1 Sep 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 22 Aug 2014 Planned primary completion date changed from 1 Sep 2015 to 1 Aug 2014 as reported by ClinicalTrials.gov.